{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T09:00:55Z","timestamp":1792054855221,"version":"4.4.0"},"reference-count":74,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2002,6,1]],"date-time":"2002-06-01T00:00:00Z","timestamp":1022889600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Seminars in Oncology"],"published-print":{"date-parts":[[2002,6]]},"DOI":"10.1053\/sonc.2002.33078","type":"journal-article","created":{"date-parts":[[2005,11,3]],"date-time":"2005-11-03T08:58:14Z","timestamp":1131008294000},"page":"18-26","source":"Crossref","is-referenced-by-count":167,"special_numbering":"S7","title":["Cancer immunotherapy: The interferon-\u03b1 experience"],"prefix":"10.1053","volume":"29","author":[{"given":"John","family":"Kirkwood","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1053\/sonc.2002.33078_BIB1","first-page":"4","article-title":"The human interferon-\u03b1 species and hybrid proteins","volume":"24","author":"Pestka","year":"1997","journal-title":"Semin Oncol"},{"key":"10.1053\/sonc.2002.33078_BIB2","first-page":"2489","article-title":"Biological properties of recombinant \u03b1-interferons: 40th anniversary of the discovery of interferons","volume":"56","author":"Pfeffer","year":"1998","journal-title":"Cancer Res"},{"key":"10.1053\/sonc.2002.33078_BIB3","first-page":"461","article-title":"Pharmacology of cancer biotherapeutics: Interferons","author":"Kirkwood","year":"2000"},{"key":"10.1053\/sonc.2002.33078_BIB4","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1200\/JCO.1986.4.6.900","article-title":"IFN\u03b1-2 therapy of hairy cell leukemia: A multicenter study of 64 patients","volume":"4","author":"Golomb","year":"1986","journal-title":"J Clin Oncol"},{"key":"10.1053\/sonc.2002.33078_BIB5","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1200\/JCO.1993.11.6.1092","article-title":"Gallium scans in patients with mediastinal Hodgkin's disease treated with chemotherapy","volume":"11","author":"Cooper","year":"1993","journal-title":"J Clin Oncol"},{"key":"10.1053\/sonc.2002.33078_BIB6","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/0959-8049(94)00452-B","article-title":"A comparison of polychemotherapy and melphalan\/prednisone for primary remission induction, and interferon-alpha for maintenance treatment, in multiple myeloma. A prospective trial of the German Myeloma Treatment Group","volume":"31A","author":"Peest","year":"1995","journal-title":"Eur J Cancer"},{"key":"10.1053\/sonc.2002.33078_BIB7","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1038\/bjc.1988.17","article-title":"A randomized trial of maintenance versus no maintenance melphalan and prednisone in responding multiple myeloma patients","volume":"57","author":"Belch","year":"1988","journal-title":"Br J Cancer"},{"key":"10.1053\/sonc.2002.33078_BIB8","first-page":"155","article-title":"Role of interferon in multiple myeloma","volume":"11","author":"Joshua","year":"1997","journal-title":"J Clin Oncol"},{"issue":"suppl 2","key":"10.1053\/sonc.2002.33078_BIB9","first-page":"114","article-title":"Maintenance therapy for remission in myeloma with Intron A following high-dose melphalan and either an autologous bone marrow transplantation or peripheral stem cell rescue","volume":"13","author":"Powles","year":"1995","journal-title":"Stem Cells"},{"key":"10.1053\/sonc.2002.33078_BIB10","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/S0959-8049(97)10159-9","article-title":"Systemic adjuvant treatment of high-risk melanoma: The role of interferon alfa-2B and other immunotherapies","volume":"34","author":"Kirkwood","year":"1998","journal-title":"Eur J Cancer"},{"key":"10.1053\/sonc.2002.33078_BIB11","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S1359-6101(01)00022-3","article-title":"Interferon-alpha in tumor immunity and immunotherapy","volume":"13","author":"Belardelli","year":"2002","journal-title":"Cytokine Growth Fact Rev"},{"key":"10.1053\/sonc.2002.33078_BIB12","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1200\/JCO.1996.14.1.7","article-title":"Interferon alfa-2B adjuvant therapy of high risk resected cutaneous melanoma: The Eastern Cooperative Oncology Group trial EST 1684","volume":"14","author":"Kirkwood","year":"1996","journal-title":"J Clin Oncol"},{"key":"10.1053\/sonc.2002.33078_BIB13","doi-asserted-by":"crossref","first-page":"2370","DOI":"10.1200\/JCO.2001.19.9.2370","article-title":"High-dose interferon alfa-2b significantly prolonged relapse-free and overall survival compared with the GM-2-KLH\/QS-21 vaccine in patients with resected stage IIB-III melanoma: Results of intergroup trial E1694\/S9512\/C509801","volume":"19","author":"Kirkwood","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1053\/sonc.2002.33078_BIB14","doi-asserted-by":"crossref","first-page":"2444","DOI":"10.1200\/JCO.2000.18.12.2444","article-title":"High-and low-dose interferon alfa-2b in high-risk melanoma: First analysis of intergroup trial E1690\/S9111\/C9190","volume":"18","author":"Kirkwood","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1053\/sonc.2002.33078_BIB15","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1159\/000012085","article-title":"The emerging role of cytokines in the treatment of advanced melanoma. For the EORTC Melanoma Cooperative Group","volume":"58","author":"Keilholz","year":"2000","journal-title":"Oncology"},{"key":"10.1053\/sonc.2002.33078_BIB16","first-page":"552a","article-title":"Phase III randomized trial of cisplatin, vinblastine and dacarbazine (CVD) plus interleukin-2 (IL2) and interferon-alpha-2b (INF) versus CVD in patients with metastatic melanoma","volume":"19","author":"Eton","year":"2000","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1053\/sonc.2002.33078_BIB17","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1097\/00002371-199903000-00006","article-title":"Regimens with or without interferon-alpha as treatment for metastatic melanoma and renal cell carcinoma: An overview of randomized trials","volume":"22","author":"Hernberg","year":"1999","journal-title":"J Immunother"},{"key":"10.1053\/sonc.2002.33078_BIB18","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/BF02796202","article-title":"Viewpoint on the impact of interferon in the treatment of multiple myeloma: Benefit for a small proportion of patients?","volume":"17","author":"Blade","year":"2000","journal-title":"Med Oncol"},{"key":"10.1053\/sonc.2002.33078_BIB19","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1182\/blood.V86.3.906.906","article-title":"A randomized trial comparing interferon-alpha with busulfan for newly diagnosed chronic myelogenous leukemia in chronic phase","volume":"86","author":"Ohnishi","year":"1995","journal-title":"Blood"},{"key":"10.1053\/sonc.2002.33078_BIB20","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1182\/blood.V82.3.691.691","article-title":"Chronic myelogenous leukemia: A concise update","volume":"82","author":"Kantarjian","year":"1993","journal-title":"Blood"},{"key":"10.1053\/sonc.2002.33078_BIB21","first-page":"14","article-title":"Biotherapy of chronic meyelogenous leukemia with IFN","volume":"15","author":"Ozer","year":"1988","journal-title":"Semin Oncol"},{"key":"10.1053\/sonc.2002.33078_BIB22","doi-asserted-by":"crossref","first-page":"4064","DOI":"10.1182\/blood.V84.12.4064.bloodjournal84124064","article-title":"Randomized comparison of interferon-alpha with busulfan and hydroxyurea in chronic myelogenous leukemia. The German CML Study Group","volume":"84","author":"Hehlmann","year":"1994","journal-title":"Blood"},{"key":"10.1053\/sonc.2002.33078_BIB23","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1056\/NEJM199403243301204","article-title":"Interferon-\u03b12A as compared chemotherapy for the treatment of chronic myeloid leukemia","volume":"330","year":"1994","journal-title":"N Engl J Med"},{"key":"10.1053\/sonc.2002.33078_BIB24","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1056\/NEJM199707243370402","article-title":"Interferon a-2B combined with cytarabine versus interferon alone in chronic myelogenous leukemia. For the French Chronic Myeloid Leukemia Study Group","volume":"337","author":"Guilhot","year":"1997","journal-title":"N Engl J Med"},{"key":"10.1053\/sonc.2002.33078_BIB25","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1016\/S0140-6736(95)92596-1","volume":"345","author":"Allan","year":"1995","journal-title":"Lancet"},{"key":"10.1053\/sonc.2002.33078_BIB26","doi-asserted-by":"crossref","first-page":"3195","DOI":"10.1182\/blood.V96.9.3195","article-title":"Efficacy of STI571, an abl tyrosine kinase inhibitor, in conjunction with other antileukemic agents against bcr-abl-positive cells","volume":"96","author":"Thiesing","year":"2000","journal-title":"Blood"},{"key":"10.1053\/sonc.2002.33078_BIB27","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1007\/s11894-999-0082-7","article-title":"Treatment of chronic hepatitis B: new antiviral therapies","volume":"1","author":"Yao","year":"1999","journal-title":"Curr Gastroenterol Rep"},{"issue":"suppl","key":"10.1053\/sonc.2002.33078_BIB28","doi-asserted-by":"crossref","first-page":"S12","DOI":"10.1046\/j.1440-1746.1999.01875.x","article-title":"Treatment strategies for chronic hepatitis C: Update since the 1997 National Institutes of Health Consensus Development Conference","volume":"14","author":"Ahmed","year":"1999","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1053\/sonc.2002.33078_BIB29","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1111\/j.1572-0241.1999.00919.x","article-title":"Chronic hepatitis C and interferon alpha: Conventional and cumulative meta-analyses of randomized controlled trials","volume":"94","author":"Camma","year":"1999","journal-title":"Am J Gastroenterol"},{"key":"10.1053\/sonc.2002.33078_BIB30","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1177\/030089169908500112","article-title":"Chemo-immunotherapy of advanced AIDS-related Kaposi's sarcoma","volume":"85","author":"Aversa","year":"1999","journal-title":"Tumori"},{"key":"10.1053\/sonc.2002.33078_BIB31","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1200\/JCO.1998.16.5.1736","article-title":"Prospective randomized trial of two dose levels of interferon alfa with zidovudine for the treatment of Kaposi's sarcoma associated with human immunodeficiency virus infection: A Canadian HIV Clinical Trials Network study","volume":"16","author":"Shepherd","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1053\/sonc.2002.33078_BIB32","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1002\/(SICI)1097-0142(19980915)83:6<1205::AID-CNCR21>3.0.CO;2-8","article-title":"Long-term treatment of myeloproliferative disease with interferon-\u03b12B","volume":"83","author":"Gilbert","year":"1998","journal-title":"Cancer"},{"key":"10.1053\/sonc.2002.33078_BIB33","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s002770050563","article-title":"Interferon alpha in the treatment of polycythemia vera","volume":"79","author":"Lengfelder","year":"2000","journal-title":"Ann Hematol"},{"key":"10.1053\/sonc.2002.33078_BIB34","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1159\/000052353","article-title":"Combined subcutaneous recombinant alpha-interferon and interleukin-2 in metastatic renal cell cancer: Results of the Multicentre All Ireland Immunotherapy Study Group","volume":"37","author":"Rogers","year":"2000","journal-title":"Eur Urol"},{"key":"10.1053\/sonc.2002.33078_BIB35","doi-asserted-by":"crossref","first-page":"2972","DOI":"10.1200\/JCO.2000.18.16.2972","article-title":"Phase III trial of interferon alfa-2A with or without 13-cis-retinoic acid for patients with advanced renal cell carcinoma","volume":"18","author":"Motzer","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1053\/sonc.2002.33078_BIB36","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1002\/1097-0142(20000801)89:3<597::AID-CNCR15>3.0.CO;2-E","article-title":"Infusional interleukin-2 and 5-fluorouracil with subcutaneous interferon-alpha for the treatment of patients with advanced renal cell carcinoma: A southwest oncology group phase II study","volume":"89","author":"Elias","year":"2000","journal-title":"Cancer"},{"key":"10.1053\/sonc.2002.33078_BIB37","first-page":"309","article-title":"Cytokines in combination with chemotherapy for advanced renal carcinoma\u2013The importance of patient selection","volume":"11","author":"Joffe","year":"1996","journal-title":"Cancer Biother Radiopharm"},{"key":"10.1053\/sonc.2002.33078_BIB38","doi-asserted-by":"crossref","first-page":"417","DOI":"10.3109\/07357900009032812","article-title":"Interferon alpha-2A and 13-cis-retinoic acid in patients with metastatic renal cell cancer","volume":"18","author":"Jacobs","year":"2000","journal-title":"Cancer Invest"},{"key":"10.1053\/sonc.2002.33078_BIB39","first-page":"180a","article-title":"Phase II trial of branch pegylated (40 kDa) interferon \u03b1-2a for patients with advanced renal cell carcinoma","volume":"20","author":"Motzer","year":"2000","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1053\/sonc.2002.33078_BIB40","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1054\/bjoc.2000.1340","article-title":"Capecitabine in the treatment of metastatic renal cell carcinoma","volume":"83","author":"Oevermann","year":"2000","journal-title":"Br J Cancer"},{"key":"10.1053\/sonc.2002.33078_BIB41","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1097\/00001813-200003000-00005","article-title":"Vinorelbine and interferon-alpha2c as second-line therapy in metastatic renal cell carcinoma","volume":"11","author":"Schmidinger","year":"2000","journal-title":"Anticancer Drugs"},{"key":"10.1053\/sonc.2002.33078_BIB42","first-page":"123","article-title":"Recombinant interferon-alpha 2B and megestrol acetate in patients with advanced renal cell carcinoma","volume":"83","author":"Voravud","year":"2000","journal-title":"J Med Assoc Thai"},{"key":"10.1053\/sonc.2002.33078_BIB43","first-page":"1267","article-title":"Phase I trial of combined immunotherapy with subcutaneous granulocyte macrophage colony-stimulating factor, low-dose interleukin 2, and interferon alpha in progressive metastatic melanoma and renal cell carcinoma","volume":"6","author":"de Gast","year":"2000","journal-title":"Clin Cancer Res"},{"key":"10.1053\/sonc.2002.33078_BIB44","first-page":"315","article-title":"Cytokines and tumor vaccination","volume":"11","author":"Anton","year":"1996","journal-title":"Cancer Biother Radiopharm"},{"key":"10.1053\/sonc.2002.33078_BIB45","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1016\/S0022-5347(05)67771-3","volume":"163","author":"Schwaab","year":"2000","journal-title":"J Urol"},{"key":"10.1053\/sonc.2002.33078_BIB46","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1016\/S0022-5347(17)35785-3","article-title":"Interpheron alpha primed tumor infiltrating lymphocytes combined with interleukin-2 and","volume":"150","author":"Belledegrun","year":"1993","journal-title":"J Urol"},{"key":"10.1053\/sonc.2002.33078_BIB47","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1097\/00002371-200005000-00010","article-title":"Generation of monocyte-derived dendritic cells from patients with renal cell cancer: Modulation of their functional properties after therapy with biological response modifiers (IFN-alpha plus IL-2 and IL-12)","volume":"23","author":"Merad","year":"2000","journal-title":"J Immunother"},{"key":"10.1053\/sonc.2002.33078_BIB48","doi-asserted-by":"crossref","first-page":"2859","DOI":"10.1200\/JCO.1999.17.9.2859","article-title":"Prospective randomized trial of interferon alfa-2a plus vinblastine versus vinblastine alone in patients with advanced renal cell cancer","volume":"17","author":"Pyrhonen","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1053\/sonc.2002.33078_BIB49","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1200\/JCO.1986.4.2.234","article-title":"Clinical toxicity in cancer patients","volume":"4","author":"Quesada","year":"1986","journal-title":"J Clin Oncol"},{"key":"10.1053\/sonc.2002.33078_BIB50","first-page":"9","article-title":"Safety profile of interferon-\u03b1 therapy","volume":"25","author":"Weiss","year":"1998","journal-title":"Semin Oncol"},{"key":"10.1053\/sonc.2002.33078_BIB51","first-page":"64","article-title":"Cytokines and anorexia: A brief overview","volume":"25","author":"Plata-Salaman","year":"1998","journal-title":"Semin Oncol"},{"key":"10.1053\/sonc.2002.33078_BIB52","first-page":"48","article-title":"Fatigue: Definitions, mechanisms and paradigms for study","volume":"25","author":"Dalakas","year":"1998","journal-title":"Semin Oncol"},{"key":"10.1053\/sonc.2002.33078_BIB53","first-page":"54","article-title":"Endocrine-mediated mechanisms of fatigue during treatment with interferon-\u03b1","volume":"25","author":"Jones","year":"1998","journal-title":"Semin Oncol"},{"key":"10.1053\/sonc.2002.33078_BIB54","first-page":"30","article-title":"Cytokines and brain function: Relevance to interferon-\u03b1-induced mood and cognitive changes","volume":"25","author":"Licino","year":"1998","journal-title":"Semin Oncol"},{"key":"10.1053\/sonc.2002.33078_BIB55","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1089\/jir.1997.17.141","article-title":"Antibodies to interferon-\u03b1 in treated cancer patients: Incidence and significance","volume":"17","author":"McKenna","year":"1997","journal-title":"J Interferon Cytokine Res"},{"key":"10.1053\/sonc.2002.33078_BIB56","first-page":"5547","article-title":"Subcutaneous administration of IFN-alpha and gamma in patients with metastatic renal cell carcinoma","volume":"19","author":"Koga","year":"1999","journal-title":"Anticancer Res"},{"key":"10.1053\/sonc.2002.33078_BIB57","first-page":"5593","article-title":"The role of adjuvant immunotherapy after radical nephrectomy and prognostic factors in pT3N0M0 renal cell carcinoma","volume":"19","author":"Jeon","year":"1999","journal-title":"Anticancer Res"},{"key":"10.1053\/sonc.2002.33078_BIB58","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1054\/bjoc.1999.0997","article-title":"Immunochemotherapy with interleukin-2, interferon-alpha and 5-fluorouracil for progressive metastatic renal cell carcinoma: A multicenter phase II study. Dutch Immunotherapy Working Party","volume":"82","author":"van Herpen","year":"2000","journal-title":"Br J Cancer"},{"key":"10.1053\/sonc.2002.33078_BIB59","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1200\/JCO.1992.10.7.1124","article-title":"A phase II trial of interleukin-2 and interferon alfa-2A in patients with advanced renal cell carcinoma","volume":"10","author":"Ilson","year":"1992","journal-title":"J Clin Oncol"},{"key":"10.1053\/sonc.2002.33078_BIB60","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1200\/JCO.1993.11.4.661","article-title":"Randomized phase II trial of high-dose interleukin-2 either alone or in combination with interferon alfa-2B in advanced renal cell carcinoma","volume":"11","author":"Atkins","year":"1993","journal-title":"J Clin Oncol"},{"key":"10.1053\/sonc.2002.33078_BIB61","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1200\/JCO.1993.11.7.1368","article-title":"Interferon alfa-2A in advanced renal cell carcinoma: Treatment results and survival in 159 patients with long-term follow-up","volume":"11","author":"Minasian","year":"1993","journal-title":"J Clin Oncol"},{"key":"10.1053\/sonc.2002.33078_BIB62","first-page":"1641","article-title":"Intraperitoneal chemotherapy with carboplatin and interferon alpha in the treatment of relapsed ovarian cancer: A pilot study","volume":"11","author":"Repetto","year":"1991","journal-title":"Anticancer Res"},{"issue":"suppl 4","key":"10.1053\/sonc.2002.33078_BIB63","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1016\/0277-5379(91)90555-R","article-title":"Alpha interferon: The potential drug of adjuvant therapy. Past achievements and future challenges","volume":"27","author":"Bonnem","year":"1991","journal-title":"Eur J Cancer"},{"key":"10.1053\/sonc.2002.33078_BIB64","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1159\/000246551","article-title":"Adjuvant therapy of stage IIIb melanoma with interferon alfa-2B","volume":"191","author":"Doviel","year":"1995","journal-title":"Dermatology"},{"key":"10.1053\/sonc.2002.33078_BIB65","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1016\/S0889-8588(05)70025-3","article-title":"Adjuvant interferon treatment for melanoma","volume":"12","author":"Agarwala","year":"1998","journal-title":"Hematol Oncol Clin North Am"},{"key":"10.1053\/sonc.2002.33078_BIB66","first-page":"224","article-title":"Interferon-alpha and -beta: Clinical applications: Melanoma","author":"Kirkwood","year":"2000"},{"issue":"suppl 2","key":"10.1053\/sonc.2002.33078_BIB67","first-page":"48","article-title":"Potential applications of the interferons in oncology: Lessons drawn from studies of human melanoma","volume":"13","author":"Kirkwood","year":"1986","journal-title":"Semin Oncol"},{"key":"10.1053\/sonc.2002.33078_BIB68","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1023\/A:1008384506227","article-title":"Activity of interferon-alpha in relapsed patients with diffuse large B-cell and peripheral T-cell non-Hodgkin's lymphoma","volume":"11","author":"Armitage","year":"2000","journal-title":"Ann Oncol"},{"issue":"suppl 8","key":"10.1053\/sonc.2002.33078_BIB69","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1002\/1097-0142(19860415)57:8+<1689::AID-CNCR2820571311>3.0.CO;2-M","article-title":"The role of recombinant interferon alfa-2A in the therapy of cutaneous T-cell lymphomas","volume":"57","author":"Bunn","year":"1986","journal-title":"Cancer"},{"key":"10.1053\/sonc.2002.33078_BIB70","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1097\/00002371-200101000-00007","article-title":"Meta-analysis to assess the efficacy of interferon-alpha in patients with follicular non-Hodgkin's lymphoma","volume":"24","author":"Allen","year":"2001","journal-title":"J Immunother"},{"key":"10.1053\/sonc.2002.33078_BIB71","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"7","author":"DerSimonian","year":"1986","journal-title":"Control Clin Trials"},{"key":"10.1053\/sonc.2002.33078_BIB72","first-page":"863","article-title":"A randomized study of low and high doses of leukocyte \u03b1-interferon in metastatic renal cell carcinoma: The American Cancer Society Collaborative Trial","volume":"45","author":"Kirkwood","year":"1985","journal-title":"Cancer Res"},{"key":"10.1053\/sonc.2002.33078_BIB73","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1200\/JCO.1996.14.1.7","article-title":"Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: The Eastern Cooperative Oncology Group Trial EST 1684","volume":"14","author":"Kirkwood","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1053\/sonc.2002.33078_BIB74","doi-asserted-by":"crossref","first-page":"2370","DOI":"10.1200\/JCO.2001.19.9.2370","article-title":"High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH\/QS-21 vaccine in patients with resected stage IIB-III melanoma: Results of intergroup trial E1694\/S9512\/C509801","volume":"19","author":"Kirkwood","year":"2001","journal-title":"J Clin Oncol"}],"container-title":["Seminars in Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0093775402501950?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0093775402501950?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,4,10]],"date-time":"2020-04-10T13:00:09Z","timestamp":1586523609000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0093775402501950"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,6]]},"references-count":74,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2002,6]]}},"alternative-id":["S0093775402501950"],"URL":"https:\/\/doi.org\/10.1053\/sonc.2002.33078","relation":{},"ISSN":["0093-7754"],"issn-type":[{"value":"0093-7754","type":"print"}],"subject":[],"published":{"date-parts":[[2002,6]]}}}